Abstract
Sirolimus (Rapamune), a mammalian target of Rapamycin (mTOR) inhibitor, which has been used extensively in children following solid organ transplantation, has been demonstrated to have anti-angiogenic activity in pre-clinical models. Limited experience suggests that it may have application to the treatment of vascular lesions. We describe our experience with a 1-year-old female with a kaposiform hemangioendothelioma and Kasabach-Merritt phenomenon who had rapid and dramatic response to sirolimus (0.1mg/kg/day). This case provides further rationale for clinical trials of sirolimus in the treatment of vascular lesions.
Original language | English |
---|---|
Pages (from-to) | 1396-1398 |
Number of pages | 3 |
Journal | Pediatric Blood and Cancer |
Volume | 55 |
Issue number | 7 |
DOIs | |
State | Published - Dec 2010 |
Externally published | Yes |
All Science Journal Classification (ASJC) codes
- Oncology
- Pediatrics, Perinatology, and Child Health
- Hematology